Karyopharm Therapeutics Inc. (KPTI)
After hours:
| Previous close | 1.0800 |
| Open | 1.1100 |
| Bid | 1.1100 x 600 |
| Ask | 1.1400 x 600 |
| Day's range | 1.0800 - 1.1850 |
| 52-week range | 0.6170 - 2.7900 |
| Volume | |
| Avg. volume | 1,765,009 |
| Market cap | 131.607M |
| Beta (5Y monthly) | 0.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2500 |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.57 |
PR NewswireKaryopharm to Report First Quarter 2024 Financial Results on May 8, 2024
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report first quarter 2024 financial results on Wednesday, May 8, 2024. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Wednesday, May 8, 2024, to discuss the financial results and other company updates.
- PR Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 72,700 restricted stock units (RSUs) to five newly-hired employees. These RSU awards were granted as of April 30, 2024 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Na
- PR Newswire
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that several abstracts detailing new selinexor data have been selected for presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO Annual Meeting) being held May 31 - June 4 in Chicago, IL. The Company is pleased to have received an invitation to present updated Endometrial Cancer data during a special session called "ASCO Plen
